TNFRSF10A and neoplasm: TRAIL (tumour necrosis factor-related apoptosis inducing ligand) agonist receptors, DR4 and DR5, have for more than two decades been considered as potential targets for cancer therapy owing to their ability to trigger selective apoptosis in tumour cells while sparing normal cells1,2.